Abstract: Various chalcones [(E)-1-(4-(4,6-bis(pyrimidine-2-ylamino)-1,3,5-triazine-2-ylamino) phenyl)-3(pyridine-2-yl)prop-2-en-1-one and (E)-3-(pyridine-2-yl)-1-(4-(4-(4-(E)-3-(pyridine-4-yl) acryloyl)phenylamino)-6-(pyrimdine-2-ylamino)-1,3,5-triazine-2-ylamino)phenyl)prop-2-en-1-one] prepared to react with hydroxylamine hydrochloride and hydrazine hydrate to synthesize corresponding isoxazole and pyrazole derivatives.
Introduction
s-Triazines have potential to act as therapeutic agents in the treatment of various fungal and bacterial diseases including some cancers 1 . They also have potential to act as tools of affinity-cleavage reagents for use in molecular biology 2 . Incorporation of isoxazole and pyrazole scaffolds on to the nucleus of s-triazine incorporated with pyrimidine derivatives could produce novel analogues with enhanced biological profiles [3] [4] [5] [6] [7] . In view of this, it was considered worthwhile to incorporate moieties on to s-triazines to append the above heterocyclic scaffolds.
There has been considerable interest in the pyrazole and isoxazole ring system 8 , both with regard to heterocyclic chemistry and pharmacological activities of several of its derivatives 9 . Substituted pyrazoles, isoxazoles and their analogues have been used as precursors in the synthesis of various biologically active molecules. Fused pyrazoles and isoxazoles play a key role in many biological processes and considerable chemical and pharmacological properties that is why these ring systems are often incorporated into drugs designed for antiviral, antimicrobial, antitumor, antifungal, pesticidal, anticonvulsant, antihistaminic, antibiotic, antidepressant and CNS regulant [10] [11] [12] etc.
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Experimental
Materials and Methods
All the s-triazine derivatives were synthesized by following the under mentioned procedure. Intermediates (1.1) and (1.4) have been synthesized in our laboratory and were checked by elemental analysis, IR and 1 H NMR,
13
C NMR spectra and mass spectra data. Structures of all compounds were established on the basis of elemental analysis ( C NMR spectra and mass spectra data. Physical data of all the compounds were found to be consistent to the structures assigned to these molecule. Melting points were determined in open glass capillaries and are uncorrected. IR spectra were recorded on KBr (SHIMADZU) FTIR-8400S.
1 H NMR & 13 C NMR spectra were recorded on model AVANCE II 400 (BRUKER) using DMSO as solvent and TMS as an internal reference. Chemical shift are expressed in δ ppm. All chemicals and reagents were purchased from commercial sources. 
General Procedures
Preparation of (R)-N2-(4-(pyridine-2-yl)-4H-1,2-oxazin-4-yl)phenyl)-N4,N6-di(pyrimidin-2-yl)-1,3,5triazine-2,4,6-triamine (1.2)
A mixture of hydroxylamine hydrochloride (2.78 g, 0.04 mol) was added to sodium methoxide (3.24 g, 0.06 mol) in absolute methanol (30 mL) and stirred for 10 min. (E)-1-(4-(4,6-bis(pyrimidine-2-ylamino)-1,3,5-triazine-2-ylamino)phenyl)-3-(pyridine-2-yl)prop-2-en-1-one (1.1) (1.95 g, 0.004 mol) was added and the mixture was refluxed for 5 h. Most of the methanol was evaporated under reduced pressure and the mixture was poured in to ice cold water. The solid separated was then kept over night. 
Preparation of N2-(4-(5-(pyridine-3-yl)isoxazol-3-yl)phenyl)-N4-(4-(5-(pyridine-2-yl)isoxazol-3-yl)phenyl)-N6-(pyrimidin-2-yl)-1,3,5-triazine-2,4,6-triamine (1.5)
A mixture of hydroxylamine hydrochloride (2.78 g, 0.04 mol) was added to sodium methoxide 
Preparation of N2-(4-(5-(pyridine-3-yl)-1H-pyrazol-3-yl)phenyl)-N4-(4-(5-(pyridine-2-yl)-1H-pyrazol-3-yl)phenyl)-N6-(pyrimidin-2-yl)-1,3,5-triazine-2,4,6-triamine (1.6)
(E)-3-(pyridine-3-yl)-1-(4-(4-(4-(E)-3-(pyridine-2-yl) acryloyl) phenylamino)-6-( pyrimdine-2-ylamino)-1,3,5-triazine-2-ylamino )phenyl )prop-2-en-1-one (1.4) (1.23 g, 0.002 mol) and hydrazine hydrate (2.50 g, 0.04 mol) was heated under reflux for 8 h in 30 mL absolute ethanol and then cooled, the residual material was filtered off and re-crystallised from DMF/water.
Yield 
Results and Discussion
In the present work, pyrazole and isoxazole derivatives were obtained by the cyclocondensation of chalcones from their reaction with hydrazine hydrate and hydroxylamine hydrochloride respectively. A stepwise synthesis of the compounds is depicted by the schemes 1 and 2. The strategy shown in the provided schemes was formulated with the idea in mind to incorporate the biologically active pyrazole and isoxazole ring in the given chalcones, in order to enhance their biological properties for pharmacological use. Chalcones shown in the schemes were synthesized at different temperature conditions and which were further reacted with hydroxylamine hydrochloride and hydrazine hydrate in order to produce more biologically and pharmacologically active 
